Psoriatic Arthritis

The first liquid formulation of the common gout therapy is anticipated to improve instances of dosing adjustment for patients.

The immunosuppressive drug was more effective and resulted in fewer adverse events in patients with psoriasis but without psoriatic arthritis.

Madelaine A. Feldman, MD, FACR, shares about the current standard treatment rheumatoid arthritis and the hurdles to providing optimal treatment.

New data supports the use of etanercept as a monotherapy, or in combination, for the treatment of psoriatic arthritis.

Data from 2 phase 3 studies of secukinumab (Cosentyx) in patients with psoriatic arthritis and ankylosing spondylitis will be presented at an upcoming meeting.

New data from the FUTURE 5 study show that the interleukin-17A antagonist slows the progression of joint structural damage compared to placebo.

The trial is the first head-to-head clinical comparison in ankylosing spondylitis investigating the superiority of secukinumab for slowing spinal bone damage versus proposed biosimilar adalimumab.

The approval extends the rheumatoid arthritis treatment's label.

PsA is the second approved indication for Taltz in the US.

FDA to consider Xeljanz, the sole JAK inhibitor available in US, for new indication.

Infliximab-abda approved for range of gastroenterological and rheumatoid conditions.

Pso and PsA are associated with higher rates of pathological fractures.

Arthro-haptic 3D printed prototypes give patients an emotional experience.

Canadian authorities today approved Sanofi/Regeneron collaboration sarilumab.

It's well known that arthritis doesn't mix well with other conditions. But where does healthcare go with that information?

Researchers from the University of North Carolina examined the gene expression and regulation in colon tissue from patients to better understand the cellular and molecular mechanisms that make up Crohn’s disease.

With extensive literature review and expert input, the ACR and the American Association of Hip and Knee Surgeons (AAHKS) have come together to propose a set of guidelines for medication during the perioperative period for patients undergoing knee or hip arthroplasty.

Prescribing rheumatologists discussed drug interactions, costs, contraindications, and severity of side effects with less than 50% of the patients in the study to whom they had prescribed disease-modifying antirheumatic drugs.

A new study out of Ireland examined the prevalence of extra-articular manifestations in axial spondyloarthritis, and found that women were at significantly higher risk for inflammatory bowel disease and uveitis than men.

Philip Mease shared that he and his team are in the midst of preparing the content of the studies for publication to ensure continued education of psoriatic arthritis treatment.

At the ACR/ARHP annual meeting in Washington, DC, Philip Mease, MD, Swedish Medical Center, University of Washington, discussed the highlights from two psoriatic arthritis studies, OPAL Broaden and OPAL Beyond.

Nearly one-third of patients with plaque psoriasis will also be diagnosed with psoriatic arthritis. While somewhat common, this diagnosis requires a different approach to care in order to help patients better manage their symptoms.